Lyell Immunopharma annual total assets
2020
2021
2022
2023
2024
2025
Lyell Immunopharma Total Assets Growth & History (LYEL)
Lyell Immunopharma's total assets was $340.1M for fiscal 2025.
View full Lyell Immunopharma company overviewLyell Immunopharma annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $340.1M | −$150.8M | −30.72% |
| 2024 | 2024-12-31 | $490.9M | −$259.2M | −34.55% |
| 2023 | 2023-12-31 | $750.0M | −$187.5M | −20.00% |
| 2022 | 2022-12-31 | $937.6M | −$189.8M | −16.84% |
| 2021 | 2021-12-31 | $1.13B | $219.1M | +24.13% |
| 2020 | 2020-12-31 | $908.3M | — | — |
Lyell Immunopharma quarterly total assets
Q4.20
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $311.2M | −$74.3M | −19.28% |
| Q1 2026 | 2026-03-31 | $350.6M | −$79.2M | −18.42% |
| Q4 2025 | 2025-12-31 | $340.1M | −$150.8M | −30.72% |
| Q3 2025 | 2025-09-30 | $408.0M | −$211.3M | −34.12% |
| Q2 2025 | 2025-06-30 | $385.5M | −$268.7M | −41.08% |
| Q1 2025 | 2025-03-31 | $429.8M | −$264.4M | −38.09% |
| Q4 2024 | 2024-12-31 | $490.9M | −$259.2M | −34.55% |
| Q3 2024 | 2024-09-30 | $619.2M | −$175.8M | −22.11% |
| Q2 2024 | 2024-06-30 | $654.1M | −$181.2M | −21.69% |
| Q1 2024 | 2024-03-31 | $694.2M | −$186.2M | −21.15% |
| Q4 2023 | 2023-12-31 | $750.0M | −$187.5M | −20.00% |
| Q3 2023 | 2023-09-30 | $795.0M | −$182.3M | −18.65% |
| Q2 2023 | 2023-06-30 | $835.4M | −$186.3M | −18.24% |
| Q1 2023 | 2023-03-31 | $880.5M | −$191.7M | −17.88% |
| Q4 2022 | 2022-12-31 | $937.6M | −$189.8M | −16.84% |
| Q3 2022 | 2022-09-30 | $977.3M | −$221.1M | −18.45% |
| Q2 2022 | 2022-06-30 | $1.02B | −$208.2M | −16.93% |
| Q1 2022 | 2022-03-31 | $1.07B | — | — |
| Q4 2021 | 2021-12-31 | $1.13B | $219.1M | +24.13% |
| Q3 2021 | 2021-09-30 | $1.20B | — | — |
| Q2 2021 | 2021-06-30 | $1.23B | — | — |
| Q4 2020 | 2020-12-31 | $908.3M | — | — |
Lyell Immunopharma total assets trends
Over the last five fiscal years, Lyell Immunopharma's total assets decreased from $908.3M to $340.1M, a change of −$568.2M. The latest reported quarter, Q2 2026, shows $311.2M.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lyell Immunopharma source filings ↗